menu search

Merck's keytruda gets u.s. fda's nod for expanded use in lung cancer

The U.S. Food and Drug Administration on Monday approved the expanded use of Merck & Co's blockbuster immunotherapy Keytruda in early-stage patients w...

October 16, 2023, 6:58 pm

Chmp endorses merck's (mrk) keytruda expansion in gastric cancer

If approved, Merck's (MRK) Keytruda will be approved for a second indication in advanced gastric or GEJ cancer...

October 16, 2023, 12:02 pm

Olema oncology announces phase 2 monotherapy clinical results to be presented at the 2023 esmo congress

Oral presentation by Dr. Nancy U. Lin from Dana-Farber cancer Institute at 8:55 a.m. CEST/2:55 a.m. ET ...

October 16, 2023, 11:02 am

Modifi bio raises additional $4.3 million in seed funding

Financing will drive the further development of a new class of drugs targeting DNA repair defects in cancer...

October 16, 2023, 11:00 am

Volitionrx to present cancer detection abstracts at european oncology conference

VolitionRx (NYSE-A:VNRX) said it will be presenting three scientific abstracts about cancer detection t...

October 16, 2023, 10:11 am

Gsk cancer immunotherapy receives backing from key ema committee

GSK PLC (LSE:GSK, NYSE:GSK) said its cancer immunotherapy drug, Jemperli (dostarlimab), has been recom...

October 16, 2023, 4:02 am

Astrazeneca's tagrisso-chemo combo given priority review in us

The combination of AstraZeneca's cancer drug, Tagrisso, with chemotherapy has been been accepted and gr...

October 16, 2023, 2:34 am

Merck to present latest research from oncology portfolio at esmo 2023

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced that 28 abstracts featuring the latest research ...

October 16, 2023, 2:00 am

Regeneron to showcase progress from innovative oncology portfolio in several difficult-to-treat cancers at esmo

Event-free survival of investigational use of Libtayo® (cemiplimab) in neoadjuvant cutaneous squamous cell carcinoma (CSCC) from Phase 2 trial to be ...

October 15, 2023, 10:05 pm

Precede biosciences announces first scientific data from its liquid biopsy platform to be presented as an oral presentation at esmo 2023

Data from more than 400 patients across 15 cancers demonstrate the significance of the Precede approach...

October 15, 2023, 10:05 pm

Gilead sciences stock is cheap, with broad pipeline

Gilead Sciences is a California-based biopharmaceutical company with a $95 billion market cap, known for its treatments in HIV, hepatitis B, hepatitis...

October 15, 2023, 9:45 pm

Coherus announces toripalimab data at 2023 aacr-nci-eortc international conference on molecular targets and cancer therapeutics

— Data demonstrate preclinical potent T cell activation and differentiated mechanism of action and enhanced clinical efficacy irrespective of PD-L1 ...

October 14, 2023, 4:30 pm

Cogent biosciences presents preclinical data highlighting precision oncology pipeline at the 2023 aacr-nci-eortc international conference on molecular targets and cancer therapeutics

– Novel selective and reversible FGFR2 inhibitor exhibits strong potency across key primary and resistance driver mutations with potential advantage...

October 14, 2023, 4:30 pm

Prelude announces multiple clinical and preclinical poster presentations at aacr-nci-eortc international conference 

WILMINGTON, Del. and BOSTON, Oct. 14, 2023 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a clinical-stage pre...

October 14, 2023, 4:30 pm

Tscan therapeutics: that recent amgen deal is the only point of interest

TScan Therapeutics is developing TCR T-cell therapies for cancer using a transposon-based T cell engine...

October 14, 2023, 3:32 am

Gritstone bio: renewed excitement for its covid-19 vaccine

GRTS's COVID-19 vaccine may produce more durable immunity than current mRNA vaccines, according to data from phase 1 studies. GRTS has secured a $433 ...

October 14, 2023, 2:21 am

Processa pharmaceuticals to present at the thinkequity conference

HANOVER, MD, Oct. 13, 2023 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage ...

October 13, 2023, 5:08 pm

Illumina responds to ec grail divestiture order

Illumina Inc. ILMN, -1.10% responded Friday to an order it received Thursday from the European Commission directing the company to divest its $7.1 bil...

October 13, 2023, 2:27 pm

Illumina to divest cancer test maker grail if it does not win challenge in eu court

Illumina said on Friday it would divest cancer test maker Grail in 12 months, according to the terms of...

October 13, 2023, 2:26 pm

Fda approves pfizer's (pfe) braftovi + mektovi for lung cancer

Pfizer's (PFE) Braftovi + Mektovi drug combo gets label expansion for BRAF V600E-mutant non-small cell lung ca...

October 13, 2023, 1:31 pm


Search within

Pages Search Results: